Skip to main content
OpenTrials

Clinical trial condition

Primary Immunodeficiency Diseases

Explore clinical trials studying Primary Immunodeficiency Diseases. Study availability and eligibility vary by location and protocol.

163 public trials 32 recruiting studies
Refine in advanced search Browse all conditions

Primary Immunodeficiency Diseases trial results

Completed

Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD)

NCT00538915

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, Immune System Diseases, +3 more
Locations
  • University of Alabama Birmingham, Alabama, United States
  • Precision Trials LLC Phoenix, Arizona, United States
  • Children's Hospital of Los Angeles Los Angeles, California, United States
  • 1st Allergy and Clinical Resaerch center Centennial, Colorado, United States
View all 17 locations
View Trial Details
Completed

Phase 2/3 Study of IGSC, 20% in PIDD

NCT01218438

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, Immune System Diseases, +3 more
Locations
  • University of California, Irvine Irvine, California, United States
  • IMMUNOe International Research Centers Centennial, Colorado, United States
  • Allergy Associates of the Palm Beaches North Palm Beach, Florida, United States
  • Emory University Atlanta, Georgia, United States
View all 18 locations
View Trial Details
Completed

Gene Therapy for Wiskott-Aldrich Syndrome (WAS)

NCT01347242

Conditions
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, +13 more
Locations
  • Great Ormond Street Hospital London, United Kingdom
  • Royal Free Hospital London, United Kingdom
View Trial Details
Completed

Gammagard Liquid and rHuPH20 in PID

NCT00814320

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, Immune System Diseases, +3 more
Locations
  • Cypress, California, United States
  • Irvine, California, United States
  • Los Angeles, California, United States
  • San Francisco, California, United States
View all 14 locations
View Trial Details
Completed

Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects

NCT00546871

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, Immune System Diseases, +3 more
Locations
  • Los Angeles, California, United States
  • Centennial, Colorado, United States
  • North Palm Beach, Florida, United States
  • Atlanta, Georgia, United States
View Trial Details
Completed

Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD

NCT01485796

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, Immune System Diseases, +3 more
Locations
  • University of California, Irvine Irvine, California, United States
  • IMMUNOe International Research Centers Thornton, Colorado, United States
  • Allergy Associates of the Palm Beaches, PA North Palm Beach, Florida, United States
  • LSU Health Sciences Center & Children´s Hospital New Orleans, Louisiana, United States
View Trial Details
Completed

Immune Globulin Subcutaenous (Human), 20%

NCT01412385

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, Immune System Diseases, +3 more
Locations
  • Medizinische Universität Wien / AHK Wien (General Hospital Vienna), Universitätsklinik für Kinder- und Jugendheilkunde Vienna, Austria
  • Universitätsklinikum Erlangen, Medizinische Klinik 3 Erlangen, Germany
  • University Medical Centre Freiburg, Centre of Chronic Immunodeficiency, Divison of Rheumatology and Clinical Immunology Freiburg im Breisgau, Germany
  • Universitätsklinikum Hamburg-Eppendorf, Kinderklinik Hamburg, Germany
View Trial Details
Completed

Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously

NCT00782106

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, Immune System Diseases, +3 more
Locations
  • First Allergy and Clinical Research Center Centennial, Colorado, United States
  • Allergy Associates of the Palm Beaches North Palm Beach, Florida, United States
  • Pediatrics Allergy/Immunology Association, PA Dallas, Texas, United States
View Trial Details

Related conditions